Needham & Company Maintains a 'Buy' on OncoGenex Pharmaceuticals (OGXI); Custersin and OGX-427 Development Remain on Track

Needham & Company maintains a 'Buy' on OncoGenex Pharmaceuticals (NASDAQ: OGXI) price target of $30.00.

Analyst, Chad Messer, said, "Enrollment remains on track to complete this year for the 1,000 patient SYNERGY trial. We look for data in 4Q:13. OncoGenex recently announced the design of the Phase III ENSPIRIT trial in 2nd line NSCLC to begin this year. The trial will randomize 1,100 patients to docetaxel plus Custersin or placebo. The trial is powered to achieve a 0.8 hazard ratio in favor of the combination arm versus a 9 months assumed overall survival in the docetaxel alone at 90% power. The trial has 2 scheduled interim analyses, although neither has a stopping rule for efficacy. We also await the near term initiation of the 630-patient pivotal AFFINITY study of Custersin in combination with Jevtana in 2nd line CRPC."

For an analyst ratings summary and ratings history on OncoGenex Pharmaceuticals click here. For more ratings news on OncoGenex Pharmaceuticals click here.

Shares of OncoGenex Pharmaceuticals closed at $13.64 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Amazon.com (AMZN) PT Raised to $215 at UBS
• JPMorgan Downgrades Beijing Easpring Material Technology Co Ltd. (300073:CH) to Underweight
• First Cash Financial (FCFS) PT Lowered to $140 at TD Cowen